Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Here’s Why Moderna Shares May Blast Higher Over the Next Few Weeks

By Chris Lau, InvestorPlace Contributor

Moderna’s R&D day was a non-event, while upcoming clinical data posts may re-ignite MRNA stock buying.

Why Slack Stock Risks Another Round of Sharp Selling

By Chris Lau, InvestorPlace Contributor

Slack stock is under pressure after posting another loss and weak billings, suggesting lukewarm results for the rest of the year.

Bet on Norwegian Cruise Line Stock Sailing to Higher Gains

By Chris Lau, InvestorPlace Contributor

Norwegian Cruise Line stock enjoyed a steady uptrend since March as investors bet bookings will climb and revenue recovers quickly.

Stay Away From Jumia as Product Quality Worsens

By Chris Lau, InvestorPlace Contributor

Jumia posted a weak outlook ahead because unsatisfied customers are not coming back, suggesting high risks in holding JMIA stock.

7 Undervalued Stocks to Buy Before They’re Blasting off Again

By Chris Lau, InvestorPlace Contributor

Picking deep undervalued stocks will pay off in the long-run, as the economy takes its time to fully recover from the pandemic selloff.

Load More